Streetbeat News

Revenues

VMC

Five analysts have recently updated their ratings on Vulcan Materials (NYSE:VMC), with an average 12-month price target of $242.4, down 2.13% from the previous average. Actions include ratings from 'Equal-Weight' to 'Buy' and price target changes. Vulcan Materials, a major producer of construction aggregates, showed a revenue growth of 4.67% but has a lower net margin and ROE compared to industry standards, and a high debt-to-equity ratio. Analysts' ratings are based on financial forecasts and company performance.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 6:01 pm

NVCR

NovoCure's stock is trading higher following the company's announcement of preliminary Q4 and full-year 2023 revenue guidance that exceeded analysts' expectations.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 6:01 pm

EPRT

Five analysts have recently updated their ratings on Essential Properties Realty Trust Inc (NYSE:EPRT), with a positive shift in sentiment. The average 12-month price target is now $27.65, up from $27.25. Analysts from Raymond James, B. Riley Securities, Stifel, and Truist Securities have provided ratings ranging from 'Outperform' to 'Buy', with price targets between $25.75 and $29.00. Essential Props Realty, a real estate investment trust, has shown strong financial performance with a revenue growth of 29.71%, a net margin of 49.98%, an ROE of 1.63%, an ROA of 1.04%, and a low debt-to-equity ratio of 0.56.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 6:00 pm

KEY

KeyCorp (NYSE:KEY) has received mixed analyst ratings over the past three months, with 8 analysts offering a range of perspectives. The average 12-month price target for KEY has risen to $14.75, up 12.77% from the previous target of $13.08. Analysts from firms like Keefe, Bruyette & Woods, Barclays, Goldman Sachs, Wells Fargo, Stephens & Co., RBC Capital, and Morgan Stanley have updated their ratings and price targets. KeyCorp's financials show a decline in revenue growth, below-average net margin, ROE, and ROA, and a high debt-to-equity ratio. The company, with over $170 billion in assets, operates primarily in Ohio and New York, focusing on middle-market commercial clients.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 6:00 pm

BZAMF

BZAM Ltd. has completed the acquisition of Final Bell Canada Inc., obtaining brands like Cookies, Sherbinskis, and Wyld. The deal involved issuing 90 million BZAM shares at $0.15 each to FBHI. New executives joined BZAM, and a FBHI nominee was appointed to the board. The merger aims to consolidate BZAM's market presence in Canada, combining its infrastructure with Final Bell's international brands. BZAM has also implemented cost reduction measures, resulting in a 112% increase in net revenue year-over-year. However, over 90 employees were laid off in September 2023. BZAMF's stock price saw a slight increase to $0.1028 per share.

Portfolio Pulse from Jelena Martinovic

January 08, 2024 | 5:49 pm

BLFS

BioLife Solutions shares are trading higher following the company's issuance of preliminary Q4 and FY23 revenue guidance, indicating positive performance expectations.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:38 pm

DXCM

DexCom's stock is trading higher following the release of their preliminary Q4 and full year 2023 revenue results, along with their guidance for 2024.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:32 pm

FNA

Paragon 28's stock is trading lower following the company's release of preliminary revenue guidance for Q4 and the full year of 2023, which suggests that the financial results may not meet market expectations.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:29 pm

ALHC

Alignment Healthcare's stock is trading higher following the announcement of a 44% increase in Alignment Health Plan membership, reaching approximately 155,500 members as of January 1st.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:23 pm

BRKR

Bruker Corporation provided a preliminary outlook for 2024, expecting solid, above-market growth in organic revenue and non-GAAP EPS. However, the company cautions that Q4 and FY23 results are not yet finalized or audited, and advises against placing undue reliance on these preliminary estimates.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:21 pm